Key stats
About CHINA ASSET MANAGEMENT (HK) CHINAAMC HANG SENG BIOTECH ETF HKD
Expense ratio
0.71%
Home page
Inception date
Mar 18, 2021
ISIN
HK0000711199
The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Hong Kong-Listed Biotech Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.54%
Health Technology84.90%
Health Services4.24%
Consumer Non-Durables3.60%
Commercial Services2.48%
Distribution Services2.19%
Technology Services2.13%
Bonds, Cash & Other0.46%
Cash0.46%
Stock breakdown by region
Asia100.00%
North America0.00%
Latin America0.00%
Europe0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history